Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evazarsen
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Evazarsen (IONIS-AGT-LRx) is an investigational ligand-conjugated antisense (LICA) oligonucleotide developed by Ionis Pharmaceuticals for the treatment of hypertension. It is designed to reduce the production of angiotensinogen (AGT), the sole precursor of all angiotensin peptides in the renin-angiotensin-aldosterone system (RAAS), which is primarily synthesized in the liver. By binding to AGT mRNA and promoting its degradation via RNase H1, evazarsen lowers circulating AGT levels, leading to a sustained reduction in blood pressure. The drug utilizes Ionis' GalNAc-conjugation technology to ensure targeted delivery to hepatocytes, allowing for infrequent subcutaneous administration and potentially improving long-term blood pressure control in patients with essential or resistant hypertension.
- Brand names
- evazarsen
- Other names
- IONIS AGT LRxIONIS-AGT-L Rx
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on evazarsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evazarsen.